Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 15, 2019 - Issue 2
Submit an article Journal homepage
1,247
Views
17
CrossRef citations to date
0
Altmetric
Short Report

Response to PCV13 vaccination in patients with multiple myeloma versus healthy controls

S. Shahzad MustafaDepartment of Medicine, Rochester Regional Health, Rochester, NY, USA;Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, USACorrespondence[email protected]
,
Deep ShahDepartment of Medicine, Rochester Regional Health, Rochester, NY, USAORCID Iconhttp://orcid.org/0000-0001-9152-4210
ORCID Icon,
Jonathan BressDepartment of Medicine, Rochester Regional Health, Rochester, NY, USA;Rochester Institute of Technology, Rochester, NY, USA
&
Saad JamshedDepartment of Medicine, Rochester Regional Health, Rochester, NY, USA
Pages 452-454 | Received 05 Aug 2018, Accepted 03 Oct 2018, Published online: 23 Oct 2018

References

  • American Cancer Society. Cancer facts & figures. Atlanta, Georgia: American Cancer Society; 2018.
  • Ogawara H, Handa H, Yamazaki T, Toda T, Yoshida K, Nishimoto N, Al-ma’Quol WHS, Kaneko Y, Matsushima T, Tsukamoto N, et al. High Th1/Th2 ratio in patients with multiple myeloma. Leuk Res. 2005;29:135–140. doi:10.1016/j.leukres.2004.06.003.
  • Blimark C, Holmberg E, Mellgvist UH, Landgren O, Björkholm M, Hultcrantz M, Kjellander C, Turesson I, Kristinsson SY. Multiple myeloma and infections: a population based study on 9253 multiple myeloma patients. Haematologica. 2015;100(1):107–113. doi:10.3324/haematol.2014.107714.
  • Robertson JD, Nagesh K, Jowitt SN, Dougal M, Anderson H, Mutton K, Zambon M, Scarffe JH. Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. Br J Cancer. 2000;82:1261–1265. doi:10.1054/bjoc.1999.1088.
  • Karlsson J, Andreasson B, Kondori N, Erman E, Riesbeck K, Hogevik H, Wennerås C. Comparative study of immune status to infectious agents in elderly patients with multiple myeloma, Waldenstrom’s macroglobulinemia, and monoclonal gammopathy of undetermined significance. Clin Vaccine Immunol. 2011;18:969–977. doi:10.1128/CVI.00021-11.
  • Clutterbuck EA, Lazarus R, Yu LM, Bowman J, Bateman EA, Diggle L, Angus B, Peto TE, Beverley PC, Mant D, et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis. 2012;205(9):1408. doi:10.1093/infdis/jis213.
  • Prevnar13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]). Prescribing Information. Wyeth Pharmaceuticals, Inc; 2015.
  • Pneumococcal Vaccination: Summary of who and when to vaccinate from CDC. https://www.cdc.gov/vaccines/vpd/pneumo/hcp/who-when-to-vaccinate.html.
  • Bahuaud M, Bodilis H, Malphettes M, Maugard Landre A, Matondo C, Bouscary D, Batteux F, Launay O, Fermand J-P. Immunogenicity and persistence of the 13-valent pneumococcal conjugate vaccine (PCV13) in patients with untreated smoldering multiple myeloma (SMM): A pilot study. Heliyon. 2017 Nov;3(11):e00441. doi:10.1016/j.heliyon.2017.e00441.
  • Prevnar 13 VRBPAC Adult Indication Briefing Document. Pfizer; 2011 Nov.
  • Orange, Orange JS, Ballow M, Stiehm ER, Ballas ZK, Chinen J, De La Morena M, Kumararatne D, Harville TO, Hesterberg P, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: A working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2012; 130(3):S1- S24. doi:10.1016/j.jaci.2012.07.002.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.